Evaluation of tissue and urinary survivin expression in non-muscle-invasive bladder cancer

African Journal of Urology

Volumn 18, Issue 4, 2012, Pages 143-148

  Sharaf, S ^a   Ketat, A ^a   Diab, I ^a   Dwidar, F ^a   Sameh, W ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cancer; Detection; Recurrence; Superficial; Vesical

Indexed keywords

SURVIVIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CONCENTRATING CAPACITY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; TRANSURETHRAL RESECTION; URINE CYTOLOGY; WESTERN BLOTTING;

EID: 84883602444     PISSN: 11105704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.afju.2012.08.014     Document Type: Article

References (29)

1. Sengupta N., Siddiqui E., Mumtaz F.H. Cancers of the bladder. Journal of the Royal Society for the Promotion of Health Royal Society of Health 2004, 124(September (5)):228-229.
2. Raghavan D., Shipley W.U., Garnick M.B., Russell P.J., Richie J.P. Biology and management of bladder cancer. New England Journal of Medicine 1990, 322(April 19 (16)):1129-1138.
3. Messing E.M., Young T.B., Hunt V.B., Gilchrist K.W., Newton M.A., Bram L.L., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995, 45(March (3)):387-396. [discussion 96-7].
4. Karakiewicz P.I., Benayoun S., Zippe C., Ludecke G., Boman H., Sanchez-Carbayo M., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU International 2006, 97(May (5)):997-1001.
5. Lotan Y., Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. Journal of Urology 2002, 167(January (1)):75-79.
6. van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. European Urology 2005, 47(June (6)):736-748.
7. Vrooman O.P., Witjes J.A. Urinary markers in bladder cancer. European Urology 2008, 53(May (5)):909-916.
8. Lokeshwar V.B., Habuchi T., Grossman H.B., Murphy W.M., Hautmann S.H., Hemstreet G.P., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005, 66(December (6 Suppl 1)):35-63.
9. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. American Journal of Pathology 1998, 152(January (1)):43-49.
10. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine 1997, 3(August (8)):917-921.
11. Chiou S.K., Moon W.S., Jones M.K., Tarnawski A.S. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochemical and Biophysical Research Communications 2003, 305(May 30 (2)):374-379.
12. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Journal of Urology 2004, 171(February (2 Pt 1)):626-630.
13. Kappler M., Kotzsch M., Bartel F., Fussel S., Lautenschlager C., Schmidt U., et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clinical Cancer Research 2003, 9(March (3)):1098-1104.
14. Greene F.L. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bulletin of the American College of Surgeons 2002, 87(July (7)):13-15.
15. Lopez-Beltran A., Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European Urology 2004, 46(August (2)):170-176.
16. Gerl R., Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005, 26(February (2)):263-270.
17. Margulis V., Lotan Y., Shariat S.F. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology 2008, 26(February (1)):59-65.
18. Wu Y., Wang G., Wei J., Wen X. Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Indian Journal of Medical Sciences 2005, 59(June (6)):235-242.
19. Xiao Z.J., Zheng S., Chen W., Zhang H.F., Li C.L., Gao Y.N. Expression of survivin in transitional cell carcinoma of urinary bladder and its clinical significance. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004, 84(December 2 (23)):1977-1979.
20. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., Altieri D.C. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New England Journal of Medicine 1999, 341(August 5 (6)):452-453.
21. Ku J.H., Kwak C., Lee H.S., Park H.K., Lee E., Lee S.E. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Journal of Urology 2004, 171(February (2 Pt 1)):631-635.
22. Schultz I.J., Kiemeney L.A., Witjes J.A., Schalken J.A., Willems J.L., Swinkels D.W., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Research 2003, 23(July-August (4)):3327-3331.
23. Eissa S., Kassim S., El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Current Opinion in Obstetrics and Gynecology 2003, 15(October (5)):395-403.
24. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. Journal of the American Medical Association 2001, 285(January 17 (3)):324-328.
25. Weikert S., Christoph F., Schrader M., Krause H., Miller K., Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. International Journal of Cancer 2005, 116(August 10 (1)):100-104.
26. Moussa O., Abol-Enein H., Bissada N.K., Keane T., Ghoneim M.A., Watson D.K. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. Journal of Urology 2006, 175(June (6)):2312-2316.
27. Hou J.Q., He J., Wen D.G., Chen Z.X., Zeng J. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder. Chinese Medical Journal 2006, 119(July 5 (13)):1118-1120.
28. Eissa S., Shabayek M.I., Ismail M.F., El-Allawy R.M., Hamdy M.A. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. IUBMB Life 2010, 62(May (5)):394-399.
29. Zhao J., Tenev T., Martins L.M., Downward J., Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. Journal of Cell Science 2000, 113(December (Pt 23)):4363-4371.